Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction

Kathryn Bates, Charles E. Ruggeroli, Steven Goldman, Mohamed A. Gaballa

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Congestive heart failure (CHF) after myocardial infarction is associated with diminished endothelial nitric oxide (NO)-mediated vasorelaxation. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors have been shown to modulate vascular tone independent of the effects on lipid lowering. We hypothesized that simvastatin restores NO-dependent vasorelaxation with CHF. We found that incubation of the normal rat aorta with 0.1 mM simvastatin for 24 h enhanced ACh-mediated vasorelaxation (P < 0.05). Moreover, simvastatin increased (P < 0.05) endothelial NO synthase (eNOS) protein content by >200% (82.0 ± 14.0 vs. 21.6 ± 7.9% II/μg). In cultured endothelial cells, simvastatin (10 and 20 μM) increased eNOS levels by 114.7 ± 39.9 and 212.0 ± 75.0% II/μg protein, respectively (both P < 0.05; n = 8). In the rat coronary artery ligation model, oral gavage with 20 mg·kg -1·day -1 simvastatin for 3 wk decreased (P < 0.05) mean arterial pressure (121 ± 20 vs. 96.5 ± 10.8 mmHg) and left ventricular change in pressure with time (4,500 ± 700 vs. 4,091 ± 1,064 mmHg/s, n = 6). Simvastatin reduced (P < 0.05) basal vasoconstriction and improved ACh-mediated vasorelaxation in CHF arterial rings. Inhibition of NO generation by N G-nitro-L-arginine methyl ester (100 μM) abolished the ACh-induced vasorelaxation in all rats. In conclusion, chronic treatment of CHF with simvastatin restores endothelial NO-dependent dysfunction and upregulates eNOS protein content in arterial tissue.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume283
Issue number2 52-2
StatePublished - 2002

Fingerprint

Simvastatin
Vasodilation
Nitric Oxide
Arteries
Myocardial Infarction
Heart Failure
Hydroxymethylglutaryl CoA Reductases
NG-Nitroarginine Methyl Ester
Vasoconstriction
Ligation
Blood Vessels
Aorta
Cultured Cells
Coronary Vessels
Arterial Pressure
Proteins
Up-Regulation
Endothelial Cells
Lipids
Pressure

Keywords

  • 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors
  • Arterial relaxation
  • Congestive heart failure
  • Endothelial nitric oxide synthase

ASJC Scopus subject areas

  • Physiology

Cite this

Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction. / Bates, Kathryn; Ruggeroli, Charles E.; Goldman, Steven; Gaballa, Mohamed A.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 283, No. 2 52-2, 2002.

Research output: Contribution to journalArticle

@article{b322956dbf85434f9fa3cdb39d79e97b,
title = "Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction",
abstract = "Congestive heart failure (CHF) after myocardial infarction is associated with diminished endothelial nitric oxide (NO)-mediated vasorelaxation. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors have been shown to modulate vascular tone independent of the effects on lipid lowering. We hypothesized that simvastatin restores NO-dependent vasorelaxation with CHF. We found that incubation of the normal rat aorta with 0.1 mM simvastatin for 24 h enhanced ACh-mediated vasorelaxation (P < 0.05). Moreover, simvastatin increased (P < 0.05) endothelial NO synthase (eNOS) protein content by >200{\%} (82.0 ± 14.0 vs. 21.6 ± 7.9{\%} II/μg). In cultured endothelial cells, simvastatin (10 and 20 μM) increased eNOS levels by 114.7 ± 39.9 and 212.0 ± 75.0{\%} II/μg protein, respectively (both P < 0.05; n = 8). In the rat coronary artery ligation model, oral gavage with 20 mg·kg -1·day -1 simvastatin for 3 wk decreased (P < 0.05) mean arterial pressure (121 ± 20 vs. 96.5 ± 10.8 mmHg) and left ventricular change in pressure with time (4,500 ± 700 vs. 4,091 ± 1,064 mmHg/s, n = 6). Simvastatin reduced (P < 0.05) basal vasoconstriction and improved ACh-mediated vasorelaxation in CHF arterial rings. Inhibition of NO generation by N G-nitro-L-arginine methyl ester (100 μM) abolished the ACh-induced vasorelaxation in all rats. In conclusion, chronic treatment of CHF with simvastatin restores endothelial NO-dependent dysfunction and upregulates eNOS protein content in arterial tissue.",
keywords = "3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, Arterial relaxation, Congestive heart failure, Endothelial nitric oxide synthase",
author = "Kathryn Bates and Ruggeroli, {Charles E.} and Steven Goldman and Gaballa, {Mohamed A.}",
year = "2002",
language = "English (US)",
volume = "283",
journal = "American Journal of Physiology",
issn = "0363-6143",
publisher = "American Physiological Society",
number = "2 52-2",

}

TY - JOUR

T1 - Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction

AU - Bates, Kathryn

AU - Ruggeroli, Charles E.

AU - Goldman, Steven

AU - Gaballa, Mohamed A.

PY - 2002

Y1 - 2002

N2 - Congestive heart failure (CHF) after myocardial infarction is associated with diminished endothelial nitric oxide (NO)-mediated vasorelaxation. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors have been shown to modulate vascular tone independent of the effects on lipid lowering. We hypothesized that simvastatin restores NO-dependent vasorelaxation with CHF. We found that incubation of the normal rat aorta with 0.1 mM simvastatin for 24 h enhanced ACh-mediated vasorelaxation (P < 0.05). Moreover, simvastatin increased (P < 0.05) endothelial NO synthase (eNOS) protein content by >200% (82.0 ± 14.0 vs. 21.6 ± 7.9% II/μg). In cultured endothelial cells, simvastatin (10 and 20 μM) increased eNOS levels by 114.7 ± 39.9 and 212.0 ± 75.0% II/μg protein, respectively (both P < 0.05; n = 8). In the rat coronary artery ligation model, oral gavage with 20 mg·kg -1·day -1 simvastatin for 3 wk decreased (P < 0.05) mean arterial pressure (121 ± 20 vs. 96.5 ± 10.8 mmHg) and left ventricular change in pressure with time (4,500 ± 700 vs. 4,091 ± 1,064 mmHg/s, n = 6). Simvastatin reduced (P < 0.05) basal vasoconstriction and improved ACh-mediated vasorelaxation in CHF arterial rings. Inhibition of NO generation by N G-nitro-L-arginine methyl ester (100 μM) abolished the ACh-induced vasorelaxation in all rats. In conclusion, chronic treatment of CHF with simvastatin restores endothelial NO-dependent dysfunction and upregulates eNOS protein content in arterial tissue.

AB - Congestive heart failure (CHF) after myocardial infarction is associated with diminished endothelial nitric oxide (NO)-mediated vasorelaxation. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors have been shown to modulate vascular tone independent of the effects on lipid lowering. We hypothesized that simvastatin restores NO-dependent vasorelaxation with CHF. We found that incubation of the normal rat aorta with 0.1 mM simvastatin for 24 h enhanced ACh-mediated vasorelaxation (P < 0.05). Moreover, simvastatin increased (P < 0.05) endothelial NO synthase (eNOS) protein content by >200% (82.0 ± 14.0 vs. 21.6 ± 7.9% II/μg). In cultured endothelial cells, simvastatin (10 and 20 μM) increased eNOS levels by 114.7 ± 39.9 and 212.0 ± 75.0% II/μg protein, respectively (both P < 0.05; n = 8). In the rat coronary artery ligation model, oral gavage with 20 mg·kg -1·day -1 simvastatin for 3 wk decreased (P < 0.05) mean arterial pressure (121 ± 20 vs. 96.5 ± 10.8 mmHg) and left ventricular change in pressure with time (4,500 ± 700 vs. 4,091 ± 1,064 mmHg/s, n = 6). Simvastatin reduced (P < 0.05) basal vasoconstriction and improved ACh-mediated vasorelaxation in CHF arterial rings. Inhibition of NO generation by N G-nitro-L-arginine methyl ester (100 μM) abolished the ACh-induced vasorelaxation in all rats. In conclusion, chronic treatment of CHF with simvastatin restores endothelial NO-dependent dysfunction and upregulates eNOS protein content in arterial tissue.

KW - 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors

KW - Arterial relaxation

KW - Congestive heart failure

KW - Endothelial nitric oxide synthase

UR - http://www.scopus.com/inward/record.url?scp=0036076664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036076664&partnerID=8YFLogxK

M3 - Article

C2 - 12124226

AN - SCOPUS:0036076664

VL - 283

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6143

IS - 2 52-2

ER -